Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Gastroenterology|August 12, 2015
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infectionEdward J Gane, Robert H Hyland, Di An, et al.
The New England Journal of Medicine|January 4, 2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without CirrhosisEdward J Gane, Catherine A Stedman, Christian Schwabe, et al.
Gastroenterology|June 1, 2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsEdward J Gane, Christian Schwabe, Robert H Hyland, et al.
Gastroenterology|November 23, 2013
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infectionEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
Hepatology International|February 18, 2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosisEdward J Gane, Régine Rouzier, Tarek Hassanein, et al.
Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Pageof 1